Global Cytomegalovirus Treatment Market 2023-2030

Description

List of Tables

Title: Global Cytomegalovirus Treatment Market Size, Share & Trends Analysis Report by Drug Type (Cidofovir, Foscarnet, Valganciclovir, and Ganciclovir), By Application (Stem Cell Transplantation, Organ Transplantation, Congenital CMV Infection, and Other Application), By Distribution Channel (Hospital pharmacies, Retail Pharmacies, and E-commerce), Forecast Period (2023-2030).

The global cytomegalovirus (CMV) treatment market is anticipated to grow at a CAGR of 5.8% during the forecast period (2023-2030). The rising prevalence of CMV retinitis and congenital CMV infection, along with increasing initiatives to create awareness regarding treatments and diagnosis of these conditions is a key factor driving the growth of the CMV treatment market. For instance, as per the updated CDC data, as of May 2022, in the US, around 150 infants are born with CMV infections every year, and a few of them have long-term health issues. CMV infection in infants generates an attenuated interferon response associated with a similar infection in the adult.

As per the same source, CMV infection and the risk of reactivation of CMV infection have been reported during pregnancy and can also lead to congenital CMV infection. Thus, the rising disease burden is anticipated to create the demand for effective treatment options, thereby driving the CMV treatment market growth. The increasing clinical trial studies for the development of new drugs are likely to drive the growth of the global market.

In April 2022, the researchers have developed a calculator external link to estimate the risk that CMV infection will pass to a fetus during pregnancy. This congenital CMV infection occurs in about 20.0% to 40.0% of cases of primary maternal CMV infection. By offering a noninvasive way to predict the chance of congenital CMV based on individual characteristics, the calculator may support healthcare provider to counsel pregnant people with CMV. Such developments are anticipated to lower the infection rate in infants.

Segmental Outlook

The global cytomegalovirus treatment market is segmented on the drug type, application, and distribution channel. Based on the drug type, the market is sub-segmented into Cidofovir, Foscarnet, Valganciclovir, and Ganciclovir. Based on the application, the market is sub-segmented into stem cell transplantation, organ transplantation, congenital CMV infection, and other application. Further, on the basis of distribution channel, the market is sub-segmented into hospital pharmacies, retail pharmacies, and E-commerce.

Regional Outlook

The global cytomegalovirus treatment market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America. Among these, North America is anticipated to hold a prominent share of the market across the globe, owing to the presence of key market players along with high healthcare expenditure. The increasing incidences of cytomegalovirus infections along with increasing awareness among consumers also play a crucial role in the regional market growth. For instance, the article published by the National Institute of Neurological Disorders and Stroke (NINDS) in July 2022 mentioned that CMV infected about 50.0% to 80.0% of adults by the age of 40 and is one of the most congenital infections in the US annually. Similarly, the CMV Canada data published in June 2021, mentioned that one in 200 Canadian infants is infected with CMV during pregnancy. The report also mentioned that 1 in 5 congenital CMV had a permanent disability such as hearing loss or developmental delay. Such an increased incidence of CMV among the North American population to create higher demand for effective treatment thereby is driving the growth of the market.

The Asia-Pacific Region is Expected to Grow at a Significant CAGR in the Global Cytomegalovirus Treatment Market

Among all regions, the Asia-Pacific region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the growing federal funding for stem cell research, which is one of the core application areas of CMV drugs. In India, the Department of Biotechnology (DBT) has supported projects for basic biology of stem cells; early and late translational research; developing gene editing technology for potential therapeutic applications and creation of animal models for various human diseases. As of 2021, the funds released by the DBT during the last three years and the current year in this area is $89.6 million.

Market Players Outlook

The major companies serving the cytomegalovirus treatment market include: F. Hoffmann-La Roche Ltd, Teva Canada Ltd., Gilead Sciences, Inc., Thermo Fisher Scientific, Inc., and Merck & Co., Inc. among others. The market players are considerably contributing to the market growth by the adoption of various strategies including funding for R&D, and new drug development, to stay competitive in the market. For instance, in September 2022, Takeda announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approval of maribavir for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).

The Report Covers:

Market value data analysis of 2022 and forecast to 2030.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global cytomegalovirus treatment market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2027352

1. Report summary

Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
- 1.2.1. By Segments
- 1.2.2. By Region

2. Market Overview and Insights

2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Findings
- 2.2.2. Recommendations
- 2.2.3. Conclusion

3. Competitive Landscape

3.1. Key Company Analysis
3.2. F. Hoffmann-La Roche Ltd.
- 3.2.1. Overview
- 3.2.2. Financial Analysis
- 3.2.3. SWOT Analysis
- 3.2.4. Recent Developments
3.3. Gilead Sciences, Inc.
- 3.3.1. Overview
- 3.3.2. Financial Analysis
- 3.3.3. SWOT Analysis
- 3.3.4. Recent Developments
3.4. Teva Canada Ltd.
- 3.4.1. Overview
- 3.4.2. Financial Analysis
- 3.4.3. SWOT Analysis
- 3.4.4. Recent Developments
3.5. Key Strategy Analysis

4. Market Segmentation

4.1. Global Cytomegalovirus Treatment Market by Drug Type
- 4.1.1. Cidofovir
- 4.1.2. Foscarnet
- 4.1.3. Valganciclovir
- 4.1.4. Ganciclovir
4.2. Global Cytomegalovirus Treatment Markey by Application
- 4.2.1. Stem Cell Transplantation
- 4.2.2. Organ Transplantation
- 4.2.3. Congenital CMV Infection
- 4.2.4. Other Application
4.3. Global Cytomegalovirus Treatment Market by Distribution Channel
- 4.3.1. Hospital Pharmacies
- 4.3.2. Retail Pharmacies
- 4.3.3. E-Commerce

5. Regional Analysis

5.1. North America
- 5.1.1. United States
- 5.1.2. Canada
5.2. Europe
- 5.2.1. UK
- 5.2.2. Germany
- 5.2.3. Italy
- 5.2.4. Spain
- 5.2.5. France
- 5.2.6. Rest of Europe
5.3. Asia-Pacific
- 5.3.1. China
- 5.3.2. India
- 5.3.3. Japan
- 5.3.4. South Korea
- 5.3.5. Rest of Asia-Pacific
5.4. Rest of the World

6. Company Profiles

6.1. AiCuris Anti-infective Cures GmbH
6.2. Chimerix, Inc.
6.3. Clinigen Group PLC
6.4. F. Hoffmann-La Roche AG
6.5. Fresenius Kabi Canada
6.6. Genentech Inc.
6.7. Gilead Sciences, Inc.
6.8. GlaxoSmithKline plc
6.9. Merck & Co., Inc.
6.10. Moderna, Inc.
6.11. Mylan N.V
6.12. Pfizer Inc.
6.13. Takeda Pharmaceuticals
6.14. Teva Pharmaceuticals Inc
6.15. Thermo Fisher Scientific, Inc.
6.16. Vical, Inc.
6.17. ViroPharma, Inc.